Safety and Effectiveness of Percutaneous Ultrasound-Guided Galvanic Current in Tunnels of Patients with Hidradenitis Suppurativa: A Pilot Study.
Galvanic current
Hidradenitis suppurativa
Intralesional therapy
Pilot study
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
24
01
2024
accepted:
22
03
2024
medline:
28
4
2024
pubmed:
28
4
2024
entrez:
27
4
2024
Statut:
aheadofprint
Résumé
The recurrent nature of hidradenitis suppurativa (HS), even under maintained systemic treatment, makes it necessary to have effective local treatments; however, the response to these therapies is variable (44-81%). The application of galvanic current (GC) has demonstrated its utility in humans in treating lesions structurally similar to those of HS. With this background, the main objective of this study was to evaluate the efficacy and safety of ultrasound-guided percutaneous GC in inflamed and/or draining tunnels of HS. This was an open study (one-way repeated measures design over time). Patients were evaluated at 4 and 12 weeks after receiving GC. A combined clinical response at week 12 (absence of suppuration/inflammation on examination and clinical interview) was considered the principal variable of efficacy. Adverse effects potentially associated with GC were reported by telephone and at each visit. Twenty-six patients were included, with a male/female ratio of 5:8. The mean age was 35.84 (13.14) years. At 12 weeks after the administration of GC, a complete response was achieved in 77% (20/26) of the treated lesions. No serious adverse effects were observed, and the mean procedural pain assessed by the numeric rating scale was 0.03 (0.2). GC has proven to be effective and well tolerated in inflamed and draining tunnels of patients with HS.
Identifiants
pubmed: 38676840
doi: 10.1007/s13555-024-01149-5
pii: 10.1007/s13555-024-01149-5
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61. https://doi.org/10.1111/jdv.16677 .
doi: 10.1111/jdv.16677
pubmed: 32460374
Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021. https://doi.org/10.3390/cells10082094 .
doi: 10.3390/cells10082094
pubmed: 34943902
pmcid: 8699292
Molina-Leyva A, Cuenca-Barrales C. Adolescent-onset hidradenitis suppurativa: prevalence risk factors and disease features. Dermatology. 2019;235(1):45–50. https://doi.org/10.1159/000493465 .
doi: 10.1159/000493465
pubmed: 30368494
Dajnoki Z, Somogyi O, Medgyesi B, et al. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022;36(3):462–71. https://doi.org/10.1111/jdv.17779 .
doi: 10.1111/jdv.17779
pubmed: 34724272
Peñin-Franch A, García-Vidal JA, Martínez CM, et al. Galvanic current activates the NLRP3 inflammasome to promote type I collagen production in tendon. Elife. 2022. https://doi.org/10.7554/eLife.73675 .
doi: 10.7554/eLife.73675
pubmed: 35199642
pmcid: 8896827
Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. https://doi.org/10.3389/fimmu.2018.02965 .
doi: 10.3389/fimmu.2018.02965
pubmed: 30619323
pmcid: 6302105
Smith SDB, Okoye GA, Sokumbi O. Histopathology of hidradenitis suppurativa: a systematic review. Dermatopathol (Basel). 2022;9(3):251–7. https://doi.org/10.3390/dermatopathology9030029 .
doi: 10.3390/dermatopathology9030029
Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol. 2017;176(4):993–1000. https://doi.org/10.1111/bjd.15007 .
doi: 10.1111/bjd.15007
pubmed: 27564400
Tchero H, Herlin C, Bekara F, Fluieraru S, Teot L. Hidradenitis suppurativa: a systematic review and meta-analysis of therapeutic interventions. Indian J Dermatol Venereol Leprol. 2019;85(3):248–57. https://doi.org/10.4103/ijdvl.IJDVL_69_18 .
doi: 10.4103/ijdvl.IJDVL_69_18
pubmed: 30924446
Cuenca-Barrales C, Montero-Vílchez T, Sánchez-Díaz M, et al. Intralesional treatments in hidradenitis suppurativa: a systematic review. Dermatology. 2022;238(6):1084–91. https://doi.org/10.1159/000524121 .
doi: 10.1159/000524121
pubmed: 35477143
de Berná-Serna JD, García-Vidal JA, Escolar-Reina MP, et al. A new treatment for mammillary fistulas using ultrasound-guided percutaneous needle electrolysis. J Clin Med. 2020. https://doi.org/10.3390/jcm9030649 .
doi: 10.3390/jcm9030649
pubmed: 32977482
pmcid: 7598284
García-Martínez FJ, Vilarrasa Rull E, Salgado-Boquete L, et al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatol Treat. 2021;32(3):286–90. https://doi.org/10.1080/09546634.2019.1655524 .
doi: 10.1080/09546634.2019.1655524
Suárez Valladares MJ, Eiris Salvado N, Rodríguez Prieto MA. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam. J Dermatol Sci. 2017;85(3):241–6. https://doi.org/10.1016/j.jdermsci.2016.12.014 .
doi: 10.1016/j.jdermsci.2016.12.014
pubmed: 28034606